Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Drugs In Development, 2024 report and make more profitable business decisions.
Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), which constrains movement. Symptoms include swellings in fibrous tissue, pain, fever, muscle ossification, and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.
The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) drugs in development market research report provide comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AstraZeneca PlcBrigham and Women's Hospital
Clementia Pharmaceuticals Inc
Incyte Corp
Ipsen SA
La Jolla Pharmaceutical Company
Regeneron Pharmaceuticals Inc
University of Genoa
Table of Contents
Table
Figures
Frequently asked questions